


Is Pulmonary Hypertension (PH)-Targeted Therapy With Phosphodiesterase 5 Inhibitor (PDE5i) Associated With Improved Survival in Patients With COPD and PH?

STUDY DESIGN

Retrospective data from the Pulmonary Vascular Research Institute GoDeep meta-registry of 836 patients with COPD and PH

Patients were aged > 18 years, PH group 3.1, with mean pulmonary arterial pressure > 20 mm Hg, pulmonary vascular resistance (PVR) > 2 Wood units (WU), and pulmonary artery wedge pressure ≤ 15 mm Hg

RESULTS



50% of patients received PDE5i treatment and had improved survival with hazard ratio of 0.65 (0.57-0.75)

Transplant-free survival of **85%, 63%, and 47%** in patients treated

VS

74%, 51%, and 33% in patients not treated with PDE5i

Among patients with COPD and PH, PDE5i treatment was associated with significantly improved transplant-free survival in patients with both severe (PVR > 5 WU) and moderate (PVR 2-5 WUPH).